The mutagenic potential of @entity2049 ( @entity2050 ) therapy has been evaluated both in vivo and in vitro. Analysis of @entity2008 ( @entity2008 ), @entity3731 ( @entity3731 ), mitotic and proliferation indices (PRI) were performed. The in vivo study was carried out on 30 @entity1 with @entity3762 end undergoing treatment with @entity2050 for different periods starting from 6 months up to 15 years. Plasma @entity2050 levels were also determined for each @entity1 . The results showed that the total @entity2008 and @entity3731 were significantly increased in @entity2050 -treated @entity1 . There was no significant correlation between @entity2008 and either duration of treatment or the plasma @entity2050 levels for each @entity1 . The mitotic and proliferation indices were found to be slightly but non-significantly decreased compared to control values. On the other hand, in vitro analysis showed a significant dose-dependent increase in @entity2008 and @entity3731 in @entity1 lymphocyte cultures treated with @entity2050 (4-12 microg/ml). The mitotic and proliferation indices were also found to be decreased but only significantly in case of high doses of @entity2050 (12 microg/ml). Pretreatment of @entity1 lymphocytes with @entity2493 (0.5 mM) exhibited a significant decrease in the frequencies of @entity2050 -induced @entity2008 and @entity3731 as compared with non-treated cultures. The depressed mitotic and proliferation indices were also found to be improved in cultures pretreated with @entity2493 . In conclusion, these observations suggest that @entity2050 monotherapy may lead to chromosome damaging effects (genotoxic) and the use of @entity2493 as anti-mutagenic agent for @entity1 protection against @entity2050 -induced chromosome damage should be considered.

In vivo and in vitro evaluation of the mutagenic potential of @entity2049 : does XXXX have anti-mutagenic activity?

@entity1 :: ('9606', 'Species') :: ['human', 'patients', 'patient'] @entity2050 :: ('CHEBI:51097', 'Chemical') :: ['CBZ'] @entity2493 :: ('MESH:D008550', 'Chemical') :: ['melatonin'] @entity3731 :: ('MESH:D058288', 'Disease') :: ['SCEs', 'sister chromatid exchanges'] @entity2008 :: ('MESH:D002869', 'Disease') :: ['chromosome aberrations', 'CA'] @entity3762 :: ('MESH:C562694', 'Disease') :: ['idiopathic epilepsy'] @entity2049 :: ('MESH:D002220', 'Chemical') :: ['carbamazepine']
@entity2493 :: (MESH:D008550,Chemical) :: ['melatonin']
